Abstract
Abstract Tumor antigens derived from somatic mutations, or indels, are referred to as mutation-derived tumor antigens (MTAs) but are also known as neoantigens,or tumor-specific antigens. Evidence suggests that MTAs play a significant role in the endogenous adaptive immune response to tumors, and in the induced response following treatment with checkpoint inhibitors such as anti-CTLA-4 or anti-PD-1. This session will cover the concept of shared neoantigens in cancer and vaccine approaches to elicit adaptive antitumor immunity. Citation Format: Nina Bhardwaj. Personalized therapies: Neoantigen discovery and vaccination [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr SY14-02.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
